Allworth Financial LP cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 30.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,894 shares of the company’s stock after selling 1,688 shares during the quarter. Allworth Financial LP’s holdings in Medpace were worth $2,062,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of MEDP. BOKF NA grew its holdings in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its position in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after buying an additional 21 shares during the last quarter. UMB Bank n.a. lifted its stake in Medpace by 5.6% during the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after acquiring an additional 24 shares in the last quarter. Schulhoff & Co. Inc. lifted its stake in Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after acquiring an additional 25 shares in the last quarter. Finally, Balefire LLC boosted its holdings in Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock worth $217,000 after acquiring an additional 26 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.
Analysts Set New Price Targets
MEDP has been the subject of several recent analyst reports. TD Cowen upped their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Truist Financial upped their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus price target of $595.20.
Medpace Trading Up 0.7%
MEDP opened at $587.52 on Friday. The company has a 50 day moving average of $579.00 and a 200 day moving average of $504.67. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company has a market cap of $16.40 billion, a PE ratio of 34.44, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter last year, the company earned $3.10 EPS. The firm’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Medpace news, Director Fred B. Davenport, Jr. sold 7,283 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the completion of the transaction, the director owned 3,798 shares of the company’s stock, valued at $2,302,157.70. The trade was a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. This represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 134,471 shares of company stock valued at $82,151,311 over the last 90 days. 20.50% of the stock is owned by insiders.
Medpace Profile
Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.
Read More
- Five stocks we like better than Medpace
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
